Nonalcoholic Steatohepatitis (NASH) Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) INDUSTRY

2.1 Summary about Nonalcoholic Steatohepatitis (NASH) Industry

2.2 Nonalcoholic Steatohepatitis (NASH) Market Trends

2.2.1 Nonalcoholic Steatohepatitis (NASH) Production & Consumption Trends

2.2.2 Nonalcoholic Steatohepatitis (NASH) Demand Structure Trends

2.3 Nonalcoholic Steatohepatitis (NASH) Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Weight Loss Treatment

4.2.2 Insulin-Sensitizing Agents

4.2.3 Lipid-Lowering Drugs

4.2.4 Antioxidants

4.2.5 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospitals

4.3.2 Clinics

4.3.3 Research Institute

4.3.4 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Weight Loss Treatment

5.2.2 Insulin-Sensitizing Agents

5.2.3 Lipid-Lowering Drugs

5.2.4 Antioxidants

5.2.5 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospitals

5.3.2 Clinics

5.3.3 Research Institute

5.3.4 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Weight Loss Treatment

6.2.2 Insulin-Sensitizing Agents

6.2.3 Lipid-Lowering Drugs

6.2.4 Antioxidants

6.2.5 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospitals

6.3.2 Clinics

6.3.3 Research Institute

6.3.4 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Weight Loss Treatment

7.2.2 Insulin-Sensitizing Agents

7.2.3 Lipid-Lowering Drugs

7.2.4 Antioxidants

7.2.5 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospitals

7.3.2 Clinics

7.3.3 Research Institute

7.3.4 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Weight Loss Treatment

8.2.2 Insulin-Sensitizing Agents

8.2.3 Lipid-Lowering Drugs

8.2.4 Antioxidants

8.2.5 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospitals

8.3.2 Clinics

8.3.3 Research Institute

8.3.4 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Weight Loss Treatment

9.2.2 Insulin-Sensitizing Agents

9.2.3 Lipid-Lowering Drugs

9.2.4 Antioxidants

9.2.5 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospitals

9.3.2 Clinics

9.3.3 Research Institute

9.3.4 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Boehringer Ingelheim

10.1.2 Cerenis Therapeutics

10.1.3 Connexios Life Sciences

10.1.4 Genfit

10.1.5 Islet Sciences

10.1.6 Nimbus Therapeutics

10.1.7 Verva Pharmaceuticals

10.1.8 Viking Therapeutics

10.1.9 Astazeneca Plc

10.1.10 Galmed Pharmaceuticals

10.1.11 GENFIT SA

10.1.12 Gilead Science

10.1.13 Novo Nordisk

10.1.14 Immuron

10.1.15 Intercepts Pharmaceuticals

10.1.16 Enzo Biochem

10.1.17 Tobira Therapeutics

10.2 Nonalcoholic Steatohepatitis (NASH) Sales Date of Major Players (2017-2020e)

10.2.1 Boehringer Ingelheim

10.2.2 Cerenis Therapeutics

10.2.3 Connexios Life Sciences

10.2.4 Genfit

10.2.5 Islet Sciences

10.2.6 Nimbus Therapeutics

10.2.7 Verva Pharmaceuticals

10.2.8 Viking Therapeutics

10.2.9 Astazeneca Plc

10.2.10 Galmed Pharmaceuticals

10.2.11 GENFIT SA

10.2.12 Gilead Science

10.2.13 Novo Nordisk

10.2.14 Immuron

10.2.15 Intercepts Pharmaceuticals

10.2.16 Enzo Biochem

10.2.17 Tobira Therapeutics

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Nonalcoholic Steatohepatitis (NASH) Product Type Overview

Table Nonalcoholic Steatohepatitis (NASH) Product Type Market Share List

Table Nonalcoholic Steatohepatitis (NASH) Product Type of Major Players

Table Brief Introduction of Boehringer Ingelheim

Table Brief Introduction of Cerenis Therapeutics

Table Brief Introduction of Connexios Life Sciences

Table Brief Introduction of Genfit

Table Brief Introduction of Islet Sciences

Table Brief Introduction of Nimbus Therapeutics

Table Brief Introduction of Verva Pharmaceuticals

Table Brief Introduction of Viking Therapeutics

Table Brief Introduction of Astazeneca Plc

Table Brief Introduction of Galmed Pharmaceuticals

Table Brief Introduction of GENFIT SA

Table Brief Introduction of Gilead Science

Table Brief Introduction of Novo Nordisk

Table Brief Introduction of Immuron

Table Brief Introduction of Intercepts Pharmaceuticals

Table Brief Introduction of Enzo Biochem

Table Brief Introduction of Tobira Therapeutics

Table Products & Services of Boehringer Ingelheim

Table Products & Services of Cerenis Therapeutics

Table Products & Services of Connexios Life Sciences

Table Products & Services of Genfit

Table Products & Services of Islet Sciences

Table Products & Services of Nimbus Therapeutics

Table Products & Services of Verva Pharmaceuticals

Table Products & Services of Viking Therapeutics

Table Products & Services of Astazeneca Plc

Table Products & Services of Galmed Pharmaceuticals

Table Products & Services of GENFIT SA

Table Products & Services of Gilead Science

Table Products & Services of Novo Nordisk

Table Products & Services of Immuron

Table Products & Services of Intercepts Pharmaceuticals

Table Products & Services of Enzo Biochem

Table Products & Services of Tobira Therapeutics

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Nonalcoholic Steatohepatitis (NASH) Market Forecast (Million USD) by Region 2021f-2026f

Table Global Nonalcoholic Steatohepatitis (NASH) Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Nonalcoholic Steatohepatitis (NASH) Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Nonalcoholic Steatohepatitis (NASH) Market Forecast (Million USD) Share by Demand 2021f-2026f